GlassScriptPhysician profile
Jairo Javier Puente
NPI 1447402441
$2,430.54
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $515 · 2021: $735 · 2022: $393 · 2023: $436 · 2024: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $786.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $595.63 | 2021-2024 | |
| Glaxosmithkline, LLC. | $335.19 | 2020-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $188.92 | 2021-2024 | |
| Novo Nordisk INC | $187.89 | 2020-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $142.14 | 2020-2024 | Mounjaro, Trulicity |
| Merck Sharp & Dohme LLC | $121.10 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.65 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $115.89 | 2020-2024 | Airsupra |
| Amgen INC. | $100.35 | 2020-2022 | |
| Abbott Laboratories | $73.83 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $65.19 | 2021 | |
| Exact Sciences Corporation | $64.40 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $41.32 | 2021 | |
| Astellas Pharma US INC | $38.71 | 2023-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $30.44 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $29.73 | 2021 | |
| Allergan, INC. | $25.94 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.73 | 2024 | |
| Vanda Pharmaceuticals INC. | $23.05 | 2020 | |
| Esperion Therapeutics, INC. | $22.13 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.24 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.87 | 2022 | |
| Amarin Pharma, INC. | $15.90 | 2020 | |
| Phathom Pharmaceuticals, INC. | $14.45 | 2024 | Voquezna |
| Cardiovascular Systems INC. | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jairo Puente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.